Pharmacological inhibition of NADPH oxidase (NOX) by apocynin (Apo) reduces OS and concurrently suppresses AR signaling, ameliorating BPH via the AR/TGF-β/NOX4 axis (104). Here, TGFB1 is linked to benign prostatic hyperplasia.